Dateline City:
CHICAGO
Initial Therapy with Pembrolizumab Demonstrates Robust Anti-Tumor Activity with Tumor Shrinkage in 80 Percent of Evaluable PD-L1 Positive, Advanced NSCLC Patients
Merck Initiating Phase 3 Study with Pembrolizumab Versus Platinum-Based Doublet Chemotherapy as First-Line Therapy in PD-L1 Positive, Advanced NSCLC (KEYNOTE-024)
Additional 50 Patients Enrolled in KEYNOTE-001 with Analyses Planned Using Mercks Proprietary PD-L1 Assay at One Percent and 50 Percent Cut Points
CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the first presentation of data evaluating pembrolizumab
(MK-3475), Mercks investigational anti-PD-1 antibody, as initial
therapy in patients with PD-L1 positive, advanced non-small cell lung
cancer (NSCLC).
Language:
English
Contact:
MerckMedia Contacts:Ian McConnell, (973) 901-5722orClaire Mulhearn, (908) 423-7425orInvestor Contacts:Carol Ferguson, (908) 423-4465orJustin Holko, (908) 423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more